Testing a new cancer immunotherapy after tumor removal surgery

Plain-English translation of NCT07160335 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing whether a new immunotherapy medication called works as well as Keytruda (an established immunotherapy) in helping prevent cancer from coming back after surgery. About 174 people with resected lung cancer, melanoma, or kidney cancer will receive either or Keytruda in this study, which is designed to check whether the new medication has a similar benefit and safety profile.

Immunotherapy medications like Keytruda have helped some patients stay cancer-free after surgery, but doctors want to know if this new treatment could offer similar benefits. This trial will help determine if the medication works in the same way and is as safe and effective as the current standard option.

Do you qualify?

You likely qualify if…

you are between 18 and 85 years old
you have had complete surgical removal of non-small cell lung cancer, melanoma, or high-risk kidney cancer
you are in good overall health with an ECOG performance status of 0 (able to carry out normal daily activities)
you have a BMI between 18–30 kg/m² and weigh between 50–85 kg
if you are female and able to become pregnant, you agree to use highly effective contraception or remain abstinent during and for 6 months after treatment
you have adequate organ function as confirmed by blood tests within 7 days of starting the study

You likely don't qualify if…

you are pregnant or breastfeeding
you have used illicit drugs or abused alcohol within the past 12 months
you have a history of certain other cancers or mixed cancer types in the same organ
you have certain active infections or serious medical conditions that would make the study unsafe for you
you are unable to commit to the study visits and follow-up schedule for up to 12 months

What participation looks like

If you join this study, you will be randomly assigned to receive either or Keytruda. You will receive injections of your assigned medication once every 3 weeks for up to 12 months (about 17 doses), or until your cancer returns, you develop unacceptable side effects, or you choose to stop. If you receive Keytruda first, you will switch to after 8 doses. You'll have regular visits to check your health, blood work, and imaging scans to see how well the treatment is working.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(69 sites)

United States

Oncology Physicians Network (OPN) - Glendale, Glendale, California

Oncology Physicians Network (OPN)- Los Alamitos, Los Alamitos, California

HCA, Los Angeles, California

Los Angeles Cancer Network, Los Angeles, California

Oncology Physicians Network (OPN) - San Bernardino, San Bernardino, California